NOX · ASX

Noxopharm Ltd. (ASX:NOX)

AU$0.12

 0.0 (0.0%)
ASX:Live
18/10/2024 04:10:23 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NOX Overview

NOX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NOX

Website

Noxopharm Ltd.

Telephone

61.2.9144.2223

Address

Level 20 Tower A, The Zenith 821 Pacific Highway Chatswood, New South Wales (NSW) 2067

Description

Noxopharm Ltd. engages in the research and development of drugs. It focuses on sensitizing cancer cells to radiotherapy and chemotherapy. The company was founded by Graham Kelly on October 27, 2015 and is headquartered in Chatswood, Australia.

NOX Price Chart

Key Stats

Market Cap

AU$30.68M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.16

Trade Value (12mth)

AU$6,062.00

1 week

0%

1 month

10%

YTD

44.74%

1 year

14.58%

All time high

1.59

Key Fundamentals

EPS 3 yr Growth

-65.50%

EBITDA Margin

N/A

Operating Cashflow

-$1m

Free Cash Flow Return

-9.40%

ROIC

-49.10%

Interest Coverage

-224.70

Quick Ratio

3.80

Other Data

Shares on Issue (Fully Dilluted)

292m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.09

NOX Announcements

Latest Announcements

Date Announcements

14 October 24

AGM Letter of Access, Notice of Meeting and Proxy

×

AGM Letter of Access, Notice of Meeting and Proxy

14 October 24

Minor correction to funding announcement

×

Minor correction to funding announcement

11 October 24

Unlisted Options Upcoming Expiry

×

Unlisted Options Upcoming Expiry

10 October 24

SOF-SKN manufacturer signed for HERACLES clinical trial

×

SOF-SKN manufacturer signed for HERACLES clinical trial

30 September 24

Annual Report to shareholders

×

Annual Report to shareholders

27 September 24

New funding from sophisticated investors

×

New funding from sophisticated investors

27 September 24

Proposed issue of securities - NOX

×

Proposed issue of securities - NOX

27 September 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

27 September 24

Audited Financial Statements

×

Audited Financial Statements

17 September 24

Completes SOF-SKN formulation as clinical trial approaches

×

Completes SOF-SKN formulation as clinical trial approaches

06 September 24

Advanced funding secured ahead of R&D rebate

×

Advanced funding secured ahead of R&D rebate

03 September 24

Significant results from new brain cancer drugs

×

Significant results from new brain cancer drugs

30 August 24

Ceasing to be a substantial holder - Goodridge

×

Ceasing to be a substantial holder - Goodridge

29 August 24

Appendix 4E Preliminary Final Report

×

Appendix 4E Preliminary Final Report

19 August 24

Noxopharm Targets Clinical Trial for First-in-Class Drug

×

Noxopharm Targets Clinical Trial for First-in-Class Drug

14 August 24

Significant CRO-67 Results in Pancreatic Cancer Studies

×

Significant CRO-67 Results in Pancreatic Cancer Studies

23 July 24

June 2024 Quarterly Activities Report and Appendix 4C

×

June 2024 Quarterly Activities Report and Appendix 4C

28 May 24

Noxopharm joins global Alliance for mRNA Medicines

×

Noxopharm joins global Alliance for mRNA Medicines

14 May 24

Milestone reached as SOF-SKN progresses to next level

×

Milestone reached as SOF-SKN progresses to next level

29 April 24

March 2024 Quarterly Activities Report and Appendix 4C

×

March 2024 Quarterly Activities Report and Appendix 4C

04 April 24

Tour de Cure Grant for Brain Cancer Research

×

Tour de Cure Grant for Brain Cancer Research

27 February 24

Appendix 4D and Half Year 2024 Financial Report

×

Appendix 4D and Half Year 2024 Financial Report

13 February 24

Noxopharm extends Hudson Institute strategic partnership

×

Noxopharm extends Hudson Institute strategic partnership

22 January 24

December 2023 Quarterly Activities Report and Appendix 4C

×

December 2023 Quarterly Activities Report and Appendix 4C

18 December 23

Notification of cessation of securities - NOX

×

Notification of cessation of securities - NOX

NOX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.05 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.05 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -81.1 19.7 76.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.04 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 31.4 -19.5 55.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -24.2 -87.1 -3.5 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.08 0.03 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.08 0.03 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.7 -62.4 -39.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 291 292 292 Lock Lock Lock
Basic m Lock Lock Lock Lock 291 292 292 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 15 16 7 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.1 40.9 98.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -15 -16 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.2 -10.0 57.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -17 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -4.1 -9.1 57.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -24 -21 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -5 -6 -2 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -19 -15 -4 Lock Lock Lock
     Growth % Lock Lock Lock Lock -99.7 19.3 76.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -14 -11 -1 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 1 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -14 -11 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -55.2 20.3 93.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 14 3 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 27 10 7 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -14 -3 -2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 24 9 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 24 9 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.0 -62.4 -39.4 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -70.2 -148.7 -52.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -77.4 -165.9 -65.1 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -46.5 -99.5 -96.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -57.4 -90.7 -49.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -42.2 -66.0 -9.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -193.3 -401.0 -224.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.9 0.2 0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -57.4 -33.2 -42.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 9.1 9.5 3.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 8.6 9.5 3.8 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 67.3 32.8 48.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -602.1 -1,137.7 -54.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.4 0.3 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -70.2 -148.7 -52.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -77.4 -165.9 -65.1 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -77.4 -165.9 -65.1 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 1,017.5 1,354.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,017.5 1,354.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,155.1 0.0 114,062.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -137.6 1,354.0 -114,062.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.09%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NOX Shortsell

Frequently Asked Questions

The current share price of Noxopharm Ltd. (NOX:ASX) is AU$0.12.
The 52-week high share price for Noxopharm Ltd. (NOX:ASX) is AU$0.16.
The 52-week low share price for Noxopharm Ltd. (NOX:ASX)? is AU$0.05.
Noxopharm Ltd. (NOX:ASX) does not pay a dividend.
Noxopharm Ltd. (NOX:ASX) does not pay a dividend.
Noxopharm Ltd. (NOX:ASX) has a franking level of 0.0%.
Noxopharm Ltd. (NOX:ASX) is classified in the Healthcare.
The current P/E ratio for Noxopharm Ltd. (NOX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.